Climb Bio Stock Today
| CLYM Stock | 3.54 0.21 5.60% |
PerformanceGood
| Odds Of DistressAverage
|
Climb Bio is selling at 3.54 as of the 5th of January 2026; that is 5.6 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.46. Climb Bio has 53 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. The performance scores are derived for the period starting the 16th of January 2024 and ending today, the 5th of January 2026. Click here to learn more.
Moving against Climb Stock
Climb Stock Highlights
| President CEO | BAO BCh |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Climb Bio (CLYM) is traded on NASDAQ Exchange in USA and employs 17 people. Climb Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 255.69 M. Climb Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 47.74 M outstanding shares of which 2.22 M shares are currently shorted by private and institutional investors with about 1.15 trading days to cover.
Climb Bio generates negative cash flow from operations
Check Climb Bio Probability Of Bankruptcy
Ownership AllocationClimb Bio holds a total of 47.74 Million outstanding shares. Over half of Climb Bio's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Climb Ownership Details
Climb Bio Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Climb Bio market risk premium is the additional return an investor will receive from holding Climb Bio long position in a well-diversified portfolio.
| Mean Deviation | 5.64 | |||
| Semi Deviation | 4.63 | |||
| Standard Deviation | 8.08 | |||
| Variance | 65.29 |
Climb Stock Against Markets
Climb Bio Corporate Management
| Chandra JD | VP Counsel | Profile | |
| Susan MBA | Chief Officer | Profile | |
| Jo PalmerPhillips | Chief Officer | Profile | |
| Emily CPA | Senior Officer | Profile | |
| Cindy MBA | Senior Finance | Profile | |
| Emily Pimblett | Chief Officer | Profile | |
| Nishi MD | Senior Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.